Injection of drug-eluting microspheres into tumors
Intra-tumor Injection of Drug-eluting Microspheres Loading With Chemodrug Plus Checkpoint Inhibitors and/or IL2 for Treatment of Advanced Solid Tumors
This study tests if injecting tiny drug-filled beads directly into advanced tumors can safely help people with cancer feel better and improve their treatment outcomes.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | Second Affiliated Hospital of Guangzhou Medical University Academic / other |
| Drugs / interventions | doxorubicin |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT04770207 on ClinicalTrials.gov |
What this trial studies
This study investigates the safety and clinical effects of injecting drug-eluting microspheres loaded with various drugs directly into advanced solid tumors, including hepatocellular carcinoma. The microspheres will contain a combination of immunotherapeutic agents and chemotherapeutics, such as IL2 and PD1/PDL1/CTLA4 antibodies, and will be administered under CT guidance. The efficacy and side effects of this treatment will be evaluated using established clinical standards.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 99 with advanced solid malignant tumors and a life expectancy of more than three months.
Not a fit: Patients with benign tumors, a life expectancy of less than three months, or serious medical comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a novel and effective treatment option for patients with advanced solid tumors.
How similar studies have performed: While this approach is innovative, similar studies using drug-eluting microspheres have shown promise in treating various cancers, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Solid advanced malignant tumors * Age between18 and 99 years * Life expectancy is greater than three months Exclusion Criteria: * Benign tumor * Life expectancy is less than three months * Serious medical comorbidity * Others
Where this trial is running
Guangzhou, Guangdong
- The Second Affiliated Hospital of Guangzhou Medical University — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: Zhenfeng Zhang, MD, PhD — Second Affiliated Hospital of Guangzhou Medical University
- Study coordinator: Bingjia He, MD
- Email: 464677938@qq.com
- Phone: +862039195965
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.